SAN FRANCISCO — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) ...

This is read by an automated voice. Please report any issues or inconsistencies here. Telehealth company Hims & Hers dropped its plan to offer a knockoff version of ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

A war between some of the biggest names in weight loss has abruptly ended in a mutually beneficial truce—one that might have major implications for the average person seeking obesity treatment. On ...

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs. Federal regulators are seeking to rein in the online telemedicine platform ...

Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up ...

Hims & Hers and Novo Nordisk have had a tumultuous relationship over the past couple of years. The companies formed a short-lived commercial partnership last year, only for Novo Nordisk to walk away, ...